Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 11/20 | 1.00 |
| ▸ | HTR7 | P34969 | 5/20 | 0.68 |
| ▸ | HTR3A | P46098 | 6/20 | 0.55 |
| ▸ | HTR3E | A5X5Y0 | 5/20 | 0.55 |
| ▸ | HTR3B | O95264 | 5/20 | 0.55 |
| ▸ | HTR3D | Q70Z44 | 5/20 | 0.55 |
| ▸ | HTR3C | Q8WXA8 | 5/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.55 |
| ▸ | HTR5A | P47898 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 5/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | HTR1D | P28221 | 1/20 | 0.50 |
| ▸ | HTR1B | P28222 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5231120 | 0.93 | ADRB1 (0.86) | ADRB1HTR7HTR3AHTR3EHTR3B | |
| SCHEMBL1422991 | 0.90 | ADRB1 (0.81) | ADRB1HTR7HTR3AHTR3EHTR3B | |
| SCHEMBL27642375 | 0.90 | ADRB1 (0.81) | ADRB1HTR7HTR3AHTR3EHTR3B | |
| SCHEMBL2984679 | 0.85 | ADRB1 (0.73) | ADRB1HTR7HTR3AHTR3EHTR3B | |
| SCHEMBL13900671 | 0.85 | ADRB1 (0.73) | ADRB1HTR7HTR3AHTR3EHTR3B | |
| SCHEMBL20171856 | 0.83 | ADRB1 (0.71) | ADRB1HTR7HTR3AHTR3EHTR3B | |
| SCHEMBL15217395 | 0.83 | ADRB1 (0.71) | ADRB1HTR7HTR3AHTR3EHTR3B | |
| SCHEMBL2874530 | 0.83 | ADRB1 (0.71) | ADRB1HTR7HTR3AHTR3EHTR3B | |
| SCHEMBL21760107 | 0.83 | ADRB1 (0.71) | ADRB1HTR7HTR3AHTR3EHTR3B | |
| SCHEMBL6964650 | 0.83 | ADRB1 (0.71) | ADRB1HTR7HTR3AHTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 555 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| CN-104046246-A | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PROD & CHEM | 2014-09-17 | — | — | CN | claimed |
| US-20260092134-A1 | Bioreducible Poly (Beta-Amino Ester)s For siRNA Delivery | UNIV JOHNS HOPKINS (US) | 2026-04-02 | — | — | US | disclosed |
| US-12527746-B2 | Peptide/particle delivery systems | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4642434-A2 | LIPID COMPOSITIONS ON THE BASIS OF IONIZABLE LIPIDS, USE FOR DELIVERY TO IMMUNE CELLS | Life Technologies Corporation (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12458700-B2 | Amine-containing transfection reagents and methods for making and using same | Life Technologies Corporation (US) | 2025-11-04 | — | — | US | disclosed |
| US-12371522-B2 | Bioreducible poly (beta-amino ester)s for siRNA delivery | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250136737-A1 | MULTICOMPONENT DEGRADABLE CATIONIC POLYMERS | THE JOHNS HOPKINS UNIVERSITY | 2025-05-01 | — | — | US | disclosed |
| US-20240263196-A1 | Lipid Compositions and Methods for Delivery to Immune Cells | Life Technologies Corporation | 2024-08-08 | — | — | US | disclosed |
| US-12049530-B2 | Multicomponent degradable cationic polymers | THE JOHNS HOPKINS UNIVERISTY (US) | 2024-07-30 | — | — | US | disclosed |
| US-4940705-A | VIRICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1990-07-10 | — | — | US | disclosed |
| EP-0322643-A1 | Medicines containing as a mixture interferon and 1-desoxy-piperidinoses, process for their manufacture and their use | BAYER AG (DE) | 1989-07-05 | — | — | EP | disclosed |
| EP-0313974-A1 | N-substituted derivatives of 1-desoxynojirimycine and 1-desoxymannonojirimycine, process for their preparation and their use as pharmaceuticals | BAYER AG (DE) | 1989-05-03 | — | — | EP | disclosed |
| EP-0114374-B1 | SUBSTITUTED 4-AMINOMETHYLENE CHROMANS OR CHROMENES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICINES | BAYER AG (DE) | 1986-07-23 | — | — | EP | disclosed |
| US-4563458-A | CIRCULATORY SYSTEM DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 1986-01-07 | — | — | US | disclosed |
| EP-0114374-A1 | Substituted 4-aminomethylene chromans or chromenes, process for their preparation and their use in medicines | BAYER AG (DE) | 1984-08-01 | — | — | EP | disclosed |
| US-4370329-A | Piperazine derivatives as circulation-enhancing substances | MERZ & COMPANY (DE) | 1983-01-25 | — | — | US | disclosed |
| US-4370330-A | Method of enhancing circulation with piperazines | MERZ & COMPANY (DE) | 1983-01-25 | — | — | US | disclosed |
| US-3983121-A | 1-Substituted 4-(β-2-quinolylethyl)piperazines and 1,2,3,4-tetrahydroquinolyl-ethyl analogues thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 1976-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527746-B2 | Peptide/particle delivery systems | VEGFA, IGF2BP2, MSTN | ADRB1 1326/4885HTR7 1145/4885HTR3A 2147/4885 |
| US-20250136737-A1 | MULTICOMPONENT DEGRADABLE CATIONIC POLYMERS | PEF1, FIBP, PARN | ADRB1 4466/4885HTR7 1197/4885HTR3A 1018/4885 |
| US-12458700-B2 | Amine-containing transfection reagents and methods for making and using same | SNRPA, NUDT21, SOAT2 | ADRB1 2390/4885HTR7 826/4885HTR3A 2204/4885 |
| US-12371522-B2 | Bioreducible poly (beta-amino ester)s for siRNA delivery | AARS1, SLC43A1, PHAX | ADRB1 1085/4885HTR7 3448/4885HTR3A 4002/4885 |
| US-12049530-B2 | Multicomponent degradable cationic polymers | PEF1, FIBP, PARN | ADRB1 4466/4885HTR7 1197/4885HTR3A 1018/4885 |
| US-20260092134-A1 | Bioreducible Poly (Beta-Amino Ester)s For siRNA Delivery | SLC43A1, SLC7A5, SLC7A1 | ADRB1 961/4885HTR7 4194/4885HTR3A 4257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.